These results corroborate previous studies showing the negatively effect of ARHGAP21 on GSIS (Ferreira et al, 2015), indicating that this protein may be important on glucose homeostasis and a possible target for new therapies for obesity-induce β-cell alterations and T2D onset. This evidence concerns the gene ARHGAP21 and obesity disorder.